Delivery Order SPE2DB22D2007-SPE2DB24FH6JA

The Defense Logistics Agency awarded a delivery order valued at $17,009.24 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 ml vials. This firm fixed-price, competitively awarded contract was issued on August 12, 2025, with an ultimate completion date of September 3, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside acquisition, this delivery order was open to competition among qualified...

Amerisourcebergen Drug Corp has received a $7,857.74 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to supply TECENTRIQ 840 MG/14 ML VIAL 14ML pharmaceutical products. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania by December 29, 2023. No set-aside designation was applied to this award made against an indefinite-delivery contract held by Amerisourcebergen with DLA Troop Support Medical to provide...

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,504.62 on September 19, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 10, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside award made through open competition, reflecting AmerisourceBergen's demonstrated capability to fulfill...

The Defense Logistics Agency awarded a $8,504.62 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with...

The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $34,018.40 on September 22, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tecentriq is a specialized oncology pharmaceutical product, reflecting the company's role as a...

The Defense Logistics Agency awarded a $25,189 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tecentriq Hybridza 1,875 mg 15 ml pharmaceutical product. This is a non-set-aside competitive award with an ultimate completion date of September 30, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate...

The Defense Logistics Agency awarded a $8,504.62 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 mL vials. This competitively awarded, firm fixed-price contract is scheduled for completion by May 15, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award carries no set-aside designation, reflecting the vendor's capability to compete successfully in open procurement processes for federal...

AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tecentriq 840 mg/14 ml vials. The contract is valued at $17,009.24 under a firm fixed-price arrangement with an ultimate completion date of May 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...

The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Tecentriq 840 mg/14 ml vials. The contract is valued at $17,009.24 and operates under a firm fixed price structure with an ultimate completion date of August 11, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,016.30, is for the delivery of 840 mg/14 mL vials of the drug Tecentriq. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of December 10, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite...